Skip to content

Effect of Laser Acupuncture for Treating Monosymptomatic Nocturnal Enuresis in Adolescent Females

Effect of Laser Acupuncture for Treating Monosymptomatic Nocturnal Enuresis in Adolescent Females

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05399173
Enrollment
60
Registered
2022-06-01
Start date
2022-06-02
Completion date
2023-09-08
Last updated
2023-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Specific Urethritis

Keywords

adolescents, nocturnal enuresis

Brief summary

The aim of this study is to evaluate the effect of laser acupuncture on monosymptomatic nocturnal enuresis in adolescent females.

Detailed description

Nocturnal enuresis (NE) can be defined as the involuntary passage of urine during sleep beyond the age of anticipated nighttime bladder control, which is generally accepted as 5 years of age. IF neglected may persist into adulthood and be associated with urgency incontinence . It causes social, psychological, and emotional distress and carries a significant clinical burden. Studies show that enuretic children have lower self-esteem than healthy children. Even among chronic illnesses, enuresis has more negative effect on children's mental and social health . Most of the studies highlighted that persisting NE was a high risk of psychosocial comorbidity and negatively affects the quality of life. The feeling of helplessness of enuretic patients highlights the magnitude and complexity of the problem. Persisting enuresis adversely affects the coping, social competence, and school performance of enuretic patients when compared to their normal peers. Furthermore, a negative correlation exists between the self-esteem of an enuretic child and the chance of treatment failure . Complementary and alternative medicine (CAM) widely helped to encounter the increasing demand for non-pharmacological approaches. In recent years, there is a focus on finding cost-effective therapeutic approaches with minimal side effects to treat nocturnal enuresis . Regarding the effect of laser acupuncture on nocturnal enuresis, previous studies about the effect of low level laser acupuncture on monosymptomatic nocturnal enuresis females are limited. There was only one previous study that examined the effect of low level laser acupuncture on bladder reservoir . This study will be the first one to objectively assess the effect of laser acupuncture in monosymptomatic nocturnal enuresis by sonography. As a result, this study will have variable benefits for medical care organizations and will add to the body of knowledge of physical therapists in the scientific domain. Control group will consist of 30 females. participants will receive medical treatment (desmopressin acetate, ) per-night dose of 120 g (for 6 weeks) & advice . Study group will consist of 30 females. participants will receive the same medical treatment and advice as in group (A) in addition to low level laser therapy 3 session / week for 6 weeks. All participants will be given a full explanation of the protocol of the study and an informed consent form will be signed by each female before participating in the study .

Interventions

DEVICEinfrared (gallium aluminum arsenide laser)

Patient Position will be in supine & prone position, the area of these points is resolved utilizing anatomical landmarks and an arrangement of length measurements whose units are in respect to the physical extents of the individual patient. Acupuncture points used to treat nighttime enuresis are situated in regions that coincide with innervation by spinal sacral segments S2 through to S4 and expressed in the treatment conventions. The points of BL 23, BL 28, BL 32, RN 3, RN 4, RN 6, RN 12 impact the spinal micturition centers and parasympathetic innervation to the urinary tract, while excitement on scalp acupoints of DU 20 and DU 14 change cerebrum function through inner temporal, thalamencephalon and prefrontal cortical frameworks. Excitation of acupoints UB 20, UB 13, SP 6, ST 36, KI 3 and LU 9 are considered to strengthen spleen, vital energy and blood which encourage standardized bladder capacity

DRUGmedical treatment(desmopressin acetate)

participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) & advice

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
10 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Adolescent females have to meet the following criteria in order to participate in this study: * Suffering from Monosymptomatic nocturnal enuresis. * Their ages will range from 10-18 years. * Resistance to medical treatment (desmopressin acetate)

Exclusion criteria

* Adolescent Females with the following criteria will be excluded from this study: * Psychological or neurological disorders or other organic disorders. * Any chronic diseases. * Spinal cord abnormalities associated neurogenic bladder. * Evidence of urinary tract infection. * Ectopic ureter In addition, chronic constipation or encopresis.

Design outcomes

Primary

MeasureTime frameDescription
bladder capacityup to 6 weeksSonography for bladder capacity. It will be used to determine bladder capacity for all participants before the beginning of the study for both groups, and at end of the study

Secondary

MeasureTime frameDescription
Maximum voided volumeup to 6 weekswill be measured in all participants. using a voiding diary over 4 days before starting therapy for each female in both group A and B and after the treatment program.
Frequency of bed wetup to 6 weeksIt will be used to determine the number of bed wet for each female in both group A and B before and after the treatment program.

Countries

Egypt

Contacts

Primary ContactJehan Hu Mustafa, demonstrator
jejemustafa@gmail.com01063299714
Backup ContactJehan Hu Mustafa, demonstrator
gehan.hussien@merit.com01063299714

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026